Research Article
Public versus Private Drug Insurance and Outcomes of Patients Requiring Biologic Therapies for Inflammatory Bowel Disease
Table 5
Poisson regression model for IBD-related ED visits.
| Characteristic | Unadjusted IRR (95% CI) | Adjusted IRR (95% CI) |
| Type of drug coverage | | | Private | ref | ref | Public | 2.67 (1.57–4.55) | 2.42 (1.43–4.08) | Age | 0.99 (0.97–1.01) | 0.99 (0.97–1.01) | Age at IBD diagnosis | 0.99 (0.96–1.02) | 0.99 (0.96–1.03) | Sex | | | Male | ref | ref | Female | 1.87 (1.07–3.26) | 1.83 (1.03–3.27) | IBD subtype | | | Crohn’s disease | ref | ref | Ulcerative colitis | 0.63 (0.32–1.24) | 0.69 (0.35–1.36) | Immunomodulator use | 2.30 (1.29–4.09) | 1.87 (1.07–3.27) | Steroid dependent or refractory | 1.59 (0.93–2.70) | 1.48 (0.90–2.45) | Aggressive IBD phenotype | 0.75 (0.43–1.30) | 0.59 (0.20–1.80) | Median neighborhood income | | | 1st quintile | ref | ref | 2nd quintile | 0.75 (0.30–1.85) | 0.76 (0.35–1.65) | 3rd quintile | 0.57 (0.24–1.35) | 0.64 (0.30–1.38) | 4th quintile | 0.35 (0.12–1.00) | 0.43 (0.17–1.13) | 5th quintile | 0.81 (0.35–1.90) | 0.88 (0.40–1.94) |
|
|